Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

Market Cap	306.99B
Revenue (ttm)	26.00B
Net Income (ttm)	5.45B
Shares Out	6.36B
EPS (ttm)	0.86
PE Ratio	56.15
Forward PE	51.64
Dividend	0.20 (0.41%)
Ex-Dividend Date	Jul 12, 2024

Volume	97,511,816
Average Volume	40,956,357
Open	46.70
Previous Close	46.50
Day's Range	46.53 - 48.48
52-Week Range	37.24 - 57.53
Beta	0.28
RSI	67.57
Earnings Date	Mar 31, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 19,611
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2023, Jiangsu Hengrui Medicine's revenue was 22.82 billion, an increase of 7.26% compared to the previous year's 21.28 billion. Earnings were 4.30 billion, an increase of 10.14%.